Competing interests
Arnold Ganser
Richard F. Schlenk: Consulting for or advisory board membership with Daiichi Sankyo, Pfizer, Astellas, and Novartis; research funding from PharmaMar, AstraZeneca, Pfizer, Roche, Boehringer Ingelheim, and Daiichi Sankyo; travel, accommodations, and expenses covered by Daiichi Sankyo. Hartmut Döhner: Consulting or advisory board: AbbVie, Agios, Amgen, Astellas, AstraZeneca, Berlin-Chemie, BMS, Celgene, Daiichi Sankyo, Gilead, Janssen, Jazz, Novartis, Servier, Syndax; Clinical Research Funding to Institution: AbbVie, Agios, Amgen, Astellas, Bristol Myers Squibb, Celgene, Jazz Pharmaceuticals, Kronos Bio, Novartis, Pfizer. Helmut R. Salih: Consulting for or advisory board membership with BMS, Celgene, Novartis, Pfizer, Roche, Synimmune GmbH; research funding from ABL Bio, Celgene, Novartis, Synimmune GmbH. Arnold Ganser: Consultant or advisory board: Celgene, JAZZ Pharmaceuticals, Novartis. Elisabeth Koller: Consulting or advisory board: AbbVie, Astellas, BMS, Celgene, Daiichi Sankyo, Jazz, Novartis, Servier, Pfizer. Felicitas Thol: Advisory Board for BMS, Abbvie, Takeda, Novartis, Pfizer. All others have declared no conflicts of interest.